Aurinia Pharmaceuticals Inc. (AUPH) — closed signal from September 2, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 1, 2025.
Predicted vs. what happened
What happened
Reached its target in 63 days.
The thesis — published September 2, 2025
Aurinia delivered better-than-expected results, earning $0.16 on $70M in sales, strengthening trust in its core business. The stock looks beaten down, and the recent average price is starting to turn up, which often precedes a bounce. Steady execution and improving investor mood help limit downside, while the drug pipeline could add new growth. Over the next 0-3 months, a recovery is likely as interest returns.
Primary drivers
- Quarter's earnings and sales beat expectations, boosting confidence.
- Stock looks washed out, and the recent average price is turning upward.
- Business trends are sound and investor mood is improving steadily.
- Future drugs in development create extra ways for growth to continue.
How it played out
AUPH: target reached in 63 days
Lyra published AUPH on 2025-09-02 at 11.98 for a short-term window ending 2025-12-01. The thesis expected 25% growth. It pointed to better-than-expected results, $0.16 in earnings on $70M in sales, a beaten-down stock, a recent average price starting to turn up, steadier business trends, improving investor mood, and future drugs in development.
Inside the window, AUPH rose past the 14.98 target. It reached the target in 63 days and later peaked at 16.48 on 2025-11-26, a 37.6% gain. It ended at 16.17 on 2025-12-01. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.